Dacryocystitis refers to inflammation of nasolacrimal sac caused by obstruction within nasolacrimal duct and subsequent stagnation in the lacrimal sac. It occurs normally with high incidence rates and treatment choice depends on the indication of dacryocystitis.
Oral antibiotics targeting gram positive organisms, particularly antistaphylococcal agents for less complicated cases. However, systemic antibiotics should be considered in most complicated cases. For recurring infections, surgical evaluation should be done by ophthalmologists. Probing can be done as first-line treatment in chronic cases. Infections mostly occur in infants and in adults over the age of 40.
Dacryocystitis treatment market is expected to witness high growth owing to rise in prevalence of eye infections. Increasing clinical research and subsequent new product launches is expected to fuel growth of dacryocystitis treatment market. Scientific advancements in the developed economies is expected to fuel the market growth of dacryocystitis treatment market.
However, low healthcare expenditure is expected to hamper the future of dacryocystitis treatment market in developing economies. Less patient awareness regarding various treatment procedures may hinder the growth of dacryocystitis treatment market.
The global dacryocystitis treatment market is estimated to grow steady over forecast years owing to increasing number of surgical procedures associated with nasal and eye infections. In treatment type, antibiotics segment is expected to contribute major market share the global dacryocystitis treatment market owing to higher use of antibiotic eye drops in majority of cases.
Recently in 2017, National Eye Institute has done a study on evaluation and treatment of patients with corneal and external diseases such as dacryocystitis.
The global dacryocystitis treatment market is expected to be dominated by North America due to high product adoption rate. Latin America dacryocystitis market is expected to flourish due to increasing healthcare spending. Europe is expected to be the second most growing region in the global dacryocystitis treatment market due to extensive clinical research and technical advancements.
Increasing healthcare infrastructure in developing countries may contribute to the growth of Asia dacryocystitis treatment market. Middle East & Africa is expected to be the least lucrative region in the Dacryocystitis treatment market due to least product adoption rate and standard diagnosis.
The key players operating in the global dacryocystitis treatment market are: Pfizer Inc., Abbott Laboratories, Glaxosmithkline Plc, Mylan Inc., Cipla Limited, FCI Ophthalmics, Aurolab, Kaneka Corporation, Gunther Weiss Scientific Glass, Bess Medizintechnik GmbH, and others.
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, application, and industry.
The report on dacryocystitis treatment market is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain.
The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
The global dacryocystitis treatment market is segmented on the basis of Indication, Treatment, End user, and Region.
Based on indication, the global dacryocystitis treatment market is segmented as:
Based on treatment type, the global dacryocystitis treatment market is segmented as:
Based on sales channel, the global dacryocystitis treatment market is segmented as:
Explore Similar Insights
Dacryocystitis Treatment Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
